sergliflozin etabonate sergliflozin etabonate sergliflozin etabonate (inn/usan, codenamed gw869682x) is an investigational anti-diabetic drug being developed by glaxosmithkline. it did not undergo further development after phase ii. sergliflozin etabonateclinical dataroutes ofadministrationoralatc codenoneidentifiers iupac name 2-(4-methoxybenzyl)phenyl 6-o-(ethoxycarbonyl)-β-d-glucopyranoside cas number408504-26-7 ypubchem cid9824918iuphar/bps4587chemspider21234810 nunii4hy3523466chemblchembl450044 ncomptox dashboard (epa)dtxsid20961265 chemical and physical dataformulac23h28o9molar mass448.468 g·mol−13d model (jsmol)interactive image smiles ccoc(=o)occ1c(c(c(c(o1)oc2ccccc2cc3ccc(cc3)oc)o)o)o inchi inchi=1s/c23h28o9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26h,3,12-13h2,1-2h3 nkey:qlxkhbnjtpicnf-uhfffaoysa-n n ny (what is this?) (verify) method of action sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (sglt2), which is responsible for at least 90% of the glucose reabsorption in the kidney. blocking this transporter causes blood glucose to be eliminated through the urine. chemistry etabonate refers to the ethyl carbonate group. the remaining structure, which is the active substance, is called sergliflozin. sergliflozin